Skip to main content

“Is this the GVHD?” A qualitative exploration of quality of life issues in individuals with graft-versus-host disease following allogeneic stem cell transplant and their experiences of a specialist multidisciplinary bone marrow transplant service



Graft-versus-host disease (GVHD) is a significant cause of morbidity and mortality following allogeneic stem cell transplantation. These patients face unique challenges due to the complexity of GVHD which can affect multiple organ systems, and the toxicity of treatments. Despite the known impact on quality of life (QOL), qualitative data within the bone marrow transplantation (BMT) literature is rare, and there has been no qualitative work exploring patient experience of specialist healthcare provision for GVHD in the United Kingdom.


We conducted a primary explorative qualitative study of the experience of QOL issues and multidisciplinary care in patients with chronic GVHD following allogeneic stem cell transplantation. Eight patients were identified using convenience sampling from specialist BMT outpatient clinics. Following consent, patients were interviewed individually via telephone. Transcripts of interviews were analyzed using an inductive thematic approach.


Mean participant age was 61-years-old (range 45–68), with a mean time post-transplant of 3 years at time of interview (range 3 months–15 years). Five key QOL themes were identified: (1) ‘Restricted as to what I can do’; (2) Troubling symptoms—‘you can sort of get GVHD anywhere’; (3) Confusion/uncertainty over GVHD symptoms—‘Is this the GVHD?’; (4) Unpredictable course and uncertainty about the future; and (5) Adapting to the sick role. In addition, four themes related to experience of service provision were identified: (1) personal care and close relationship with BMT nurses; (2) efficiency versus long waits—‘On the case straight away’; (3) information provision—‘went into it with a bit of a rosy view’; and (4) the role of support groups.


These qualitative data reflect the heterogeneity of experiences of the GVHD patient population, reflecting the need for a flexible and nuanced approach to patient care with emphasis on comprehensive information provision. We have identified the key role that BMT specialist nurses within the multidisciplinary team play in supporting patients. We advocate future research should focus on ways to meet the complex needs of this patient group and ensure that the personal care and close relationships are not lost in service redesigns embracing remote consultations.


Graft-versus-host disease (GVHD) is a major complication of haematopoietic stem cell transplantation (HSCT), and a cause of significant morbidity and mortality in this patient group. GVHD is a systemic disease, able to cause pleiotropic effects in most organ systems of the body occurring at any time post-transplant [1, 2]. Both acute (aGVHD) and chronic GVHD (cGVHD) following transplantation can have a profound and lasting impact on health-related quality of life (QOL) of allogeneic stem cell transplant recipients [3]. cGVHD can persist for many years resulting in reduced functional status, inability to resume normal activities of daily living, including return to employment, and significant symptom burden [4,5,6]. Management of these patients relies on using validated and sensitive patient-reported outcome instruments (PROMs), focusing on QOL and symptom burden, to better monitor disease progression and treatment response. However, our recent systematic review of PROMs in this patient group revealed that there are limited qualitative data in the bone marrow transplant literature exploring QOL themes [7], with only 11 qualitative articles focussing on GVHD [8,9,10,11,12,13,14,15,16,17,18].

The polymorphic multi-systemic nature of GVHD and poor evidence-base for treatment options makes the diagnosis and effective management for GVHD very challenging, and the British Committee for Standards in Haematology GVHD guidelines recommend organ‐specific management and supportive care [19]. Given the diverse range of symptoms and affected organ systems that these patients experience, multidisciplinary specialist care clinics at tertiary centres have been established in the U.K. [20]. However, the patient experience of these clinics and their subjective impact on patients requires consideration. In previous qualitative work in the U.S., survivors of HSCT have expressed a preference for care from specialists, feeling that other providers did not understand the complexities of their condition [13]. Furthermore, U.S. focus groups identified concerns whereby patients felt let-down and ‘left on their own’ to deal with their cGVHD care post-HSCT [17, 18]. To our knowledge, there has been no qualitative work exploring patient experience of healthcare provision for GVHD conducted in the U.K.

The overall aim of this study was to optimize management of GVHD patients following HSCT using a cross-sectional qualitative exploration of patient perspectives of their health-related QOL (HRQOL) and experiences of service provision in a multidisciplinary specialist care clinic. The following research questions were addressed:

  1. (1)

    What are the key QOL issues that affect patients with GVHD following HSCT?

  2. (2)

    What is the patient experience of the multidisciplinary service provision for GVHD?


Ethical approval for human subject research was granted by the North West—Preston NHS Research Ethics committee in April 2019 (reference 19/NW/0198). Funding for this research was received from the Oxfordshire Health Services Research Committee (grant reference 1304). The overall research design is a thematic analysis of in-depth, semi-structured patient interviews. Thematic analysis is a key method for identifying, analysing and reporting patterns within qualitative data [21].


Participants were identified from outpatient BMT clinics held at our tertiary care, university-affiliated cancer centre. Eligible participants were adults with a confirmed diagnosis of acute or chronic GVHD following allogeneic stem cell transplant. Participants with current active malignancy, receiving inpatient care or unable or unwilling to consent were excluded. Eligibility was screened by a member of the usual clinical team (RM) who had access to the clinical notes and was able to confirm the diagnosis of GVHD. All eligible patients attending the clinic over 3 months were invited to participate in the study. A written participant information sheet was provided and signed written consent forms were completed by patients who agreed to participate. All participant responses were anonymised.


The qualitative investigator (JK) conducted in-depth, semi-structured interviews by telephone with eight individuals with GVHD between May and August 2019. All interviews were recorded using an Olympus DSS digital recorder. Each interview was approximately 1 h long and consisted of two sections. Participants were each given a payment of £50 following completion of the study interview to cover any incurred expenses. A priori themes informed by the initial results of our prior systematic review [7] were used to develop the interview schedule (“Appendix 1”). In the first section, the effect of GVHD on QOL was explored. In the second section, patient experience of the healthcare service provision was investigated, including the multidisciplinary clinics and any support services used by participants. Recordings of the interviews were transcribed verbatim by a professional transcription service and anonymised. A sample of each transcription was compared to the original audio recording to ensure accuracy.


A qualitative researcher (IDVH) undertook a qualitative thematic analysis on eight full interview transcripts, using a constant comparison and mind mapping approach [22]. The qualitative analysis software NVIVO 12 PLUS was used to manage and code the interview data. There was no pre-identified theoretical framework; all codes were derived directly from the data. Data immersion was completed (IDVH) by reading the full transcripts and coding three transcripts. A draft coding manual was developed and modifications made to the coding manual. Contradictions and ‘negative cases’ were actively sought. Once coding of data was complete, the analysis team (IDVH and JK) discussed and refined themes from the codes derived from data. Triangulation within the team provided different interpretations and perspectives to expand understanding of data. The Standards for Reporting Qualitative Research (SRQR) guideline [23] was followed in the write-up process.


Eight patients consented to participation in the study with mean time post-transplant 3 years at time of interview (see Table 1 for participant demographics). There was a range of disease severity and types of symptoms amongst participants, although we did not formally categorise severity, as the focus of our study was subjective patient experience. All participants had experienced chronic GVHD, however, they did not clearly distinguish in their accounts symptoms that might have been part of an acute GVHD picture.

Table 1 Participant demographics

Data analysis addressing QOL issues in patients with GVHD (‘Q’) identified five core themes, and data analysis addressing patient experience of the healthcare provision (‘E’) identified a further four themes: see Table 2 for a list of key themes.

Table 2 Key themes related to QOL and service provision

Themes related to QOL issues in GVHD

Theme Q1: ‘Restricted as to what I can do’

A recurring theme was that GVHD is a life-altering condition, with significant implications for an individual’s day-to-day life. There was a notable spectrum of GVHD disease severity, ranging from individuals who reported times where they were fully bed-bound with their GVHD (P6, P8), to those who made simple but significant alterations to their behaviour, for example avoiding sun exposure which could trigger GVHD of the skin (P3). One participant (P7) reported that her GVHD did not restrict her at all, aside from the time taken to apply topical ointments for her cutaneous disease. Another participant (P2) described the effect directly imposed by her ‘plethora of medical appointments’, explaining how ‘instead of doing… done all the things that we would have done in retirement, we're now shuttling backwards and forwards to Oxford.’ References to the negative psychological impact of not being able to carry out their usual daily activities were made, with one participant explaining ‘it’s quite frustrating that I can’t do the things that I want to do because I get short of breath and fatigue and nausea’ (P5).

Half of the patients did not distinguish between restricting activities because of their HSCT [for example, ‘immunosuppression means I can't mix in the same way as I did before’ (P2); ‘I haven't been able to be in contact with grandchildren because of infection risk’ (P3); restrictions on sports such as not being able to go ‘swimming… mainly due to the risk of infection’ (P5); and restrictions regarding public transport: ‘I wouldn’t be able to hack a trip into London to say nothing of going on public transport with a risk of infection’ (P8)] from those imposed by the effect of having GVHD itself. We have focussed on examples that are considered to be illustrative of restrictions imposed directly by having GVHD rather than the transplant itself, but importantly this seems to be a somewhat artificial distinction when imposed upon several of the participants’ stories. Illustrative quotations are presented in Appendix 2, Table 3.

Theme Q2: Troubling symptoms—‘you can sort of get GVHD anywhere’

Participants cited examples of a variety of different ways that GVHD had manifested. Cutaneous symptoms (all patients), fatigue (P2, P4, P5 P6, P8), and oral symptoms (P1, P2, P4) were most commonly described, but other symptoms reported included: eye dryness (P1, P2), loss of appetite (P5, P8), tendon pain (P1), ankle and leg swelling (P4) and shortness of breath (P5). Symptoms were also caused by treatment taken for GVHD symptoms, for example insomnia caused by corticosteroids (P5, P6).

There was an overlap specifically between oral symptoms and the restrictions discussed in theme 1, as participants reporting these symptoms described being forced to alter their diet for example avoiding ‘crispy’ or ‘spicy’ foods (P1). Two participants also described loss of appetite even in the absence of mouth ulceration (P5, P8).

Cutaneous symptoms provoked a variety of different reactions, ranging from embarrassment; frustration with itch or pain; distress from pain; finding treatment application regimes tedious; and the psychological impact of skin symptoms serving as a constant reminder of their GVHD. Although feelings of embarrassment were predominantly associated with skin symptoms (P3, P4), one female participant described feeling self-conscious of singing in her choir because of concern about the appearance in her mouth (P1). One participant (P5) described how his GVHD had resulted in ‘a depression’, and he alluded to the cause of this being a combination of the actual symptoms, worry about the disease and treatment side-effects—for example stating that he knew being ‘grumpy’ was a side-effect of taking oral corticosteroids. See Appendix 2, Table 4 for illustrative quotations.

Theme Q3: Confusion and uncertainty regarding GVHD symptoms—‘Is this the GVHD?’

Five of the participants described challenges arising from the non-specific nature of symptoms, with the result that it was often difficult to predict. This unpredictability often provoked anxiety, with every-day aches and pains taking on new significance as potential signs of worsening or spreading GVHD. One participant described how ‘it is just a very strange thing. You just never know, because another little thing, and I'm… 'Mm, could that be it?' you know, cos you just never know where it's going to crop up next really’ (P1).

The diverse nature of possible symptoms also led to diagnostic uncertainty, with two participants reporting consulting with multiple healthcare professionals before confirming a diagnosis of GVHD (P1, P4). One participant described being treated with oral corticosteroids for lung symptoms that could be GVHD—to ‘be on the safe side’ (P5). This sense of ambiguity regarding symptoms also led to frustration over exactly what could be treated: ‘it was just a case of I was a bit frustrated even more, you know, what the hell's going on, more than worrying about things. It was more a case of just being a bit frustrated that, you know, there's clearly something wrong here, but what it is, can we treat it?’ (P6). Furthermore, five of the patients had known co-morbidities (participant 3: severe HSV of the tongue; participant 4: chronic lymphoedema presumed secondary to GVHD and dilated cardiomyopathy; participant 5: persistent perianal fistula and haemochromatosis carrier; and participant 7: diabetes mellitus; sensory motor neuropathy and post-menopausal vulval atrophy). This is unsurprising considering the average participant age was 60, but the presence of such co-morbidities might further contribute to diagnostic uncertainty with new GVHD symptoms.

Illustrative quotations are presented in Appendix 2, Table 5.

Theme Q4: Unpredictable course and uncertainty regarding the future

The unpredictable nature of the overall disease course was also repeatedly described. This led to uncertainty about the future, with implications for planning ahead with their life plans: ‘it used to be a, you know, to look forward to growing old and everything, but now I just have to… I just literally live one day at a time and just, only look like a few months ahead’ (P4). Frustration was reported because GVHD was a slow or tumultuous recovery process and was chronic: “I suppose the recovery's been very slow, so there's been a large frustration during the recovery” (P6).

One participant, who was predominantly affected by painful oral symptoms, described her concern that the GVHD could arise somewhere in the body where it could be ‘a risk to [her] health’ (P1). However, despite worry and uncertainty about the future, and the anxiety about possible future symptoms described in theme Q3, several participants shared optimism about the future and how their GVHD would progress (P3, P6). This optimism was often cautioned by realism and had the sense of a positive outlook rather than coping through wishful thinking, for example ‘Because I'm quite strong in my mind, I've turned it round and turned the negatives into positives, so I'm back on the… I'm on a slow up, if you know what I mean’ (P4). See Appendix 2, Table 6 for illustrative quotations.

Sub-theme Q5: Adapting to the sick role

Several participants described how they found the diagnosis a ‘shock’, both in reference to the initial diagnosis which warranted a transplant (P5, P7), but also regarding the development of GVHD symptoms post-transplant (P1, P4, P6). One participant (P2) gave a sense that there was some shift in his self-identity imposed by a new life in which he must constantly take tablets and attend hospital appointments. Another participant (P8) described the difficulties keeping track of constantly changing doses of GVHD medications, which served as a ‘constant reminder’ of the condition to which he must adapt. The psychological difficulty of adapting to the diagnosis was also implied, with echoes of frustration: ‘why, what have I done?’ (P4). See Appendix 2, Table 7 for illustrative quotations.

Themes related to patient experience of the healthcare service provision

Theme E1: Personal care and close relationship with BMT nurses

Personal and attentive care was a key feature that participants described about their experience of the BMT clinics throughout the interviews. The close relationship with their named BMT nurse was the most frequent example provided, with repeated descriptions of the usefulness of having someone readily available to speak to on the telephone (P1, P2, P3, P8), for example, ‘Oh my gosh, they are wonderful. Because I have a transplant nurse… who I can call … like I called her when something else flared up a little while ago…I was in there and they saw me straight away… If I had lots of questions that I could give someone a call and maybe get some answers or… yeh, or reassurance or whatever.” (P1). Both the comfort and increased efficiency of speaking to someone who already knows your medical history was also described—as opposed to having to ‘start again’ with a new healthcare professional (P2). One participant (P4) was emphatic about the importance of being treated with attentiveness and ‘a smile’ from all members of the team.

Overall, participants were very positive about the clinical care they had received from the clinic doctors. One individual (P8) described how his consultant physician would personally call him between appointments to check in on dose adjustments or suggest alterations. This participant did have an issue, that was not further elaborated upon, with one doctor that he saw. The participant, however, reported that he spoke to his BMT specialist nurse about the issue, who arranged for him not to consult with the doctor in question again. Another participant (P6) explained that ‘there's always the thing about the logistics…it's always a tricky thing, but in terms of the expertise and the consultants I see, I've got no real issue. It's just that I see lots of different people rather than the same person.’ Illustrative quotations are presented in Appendix 2, Table 8.

Theme E2: Efficiency versus long waiting times—‘on the case straight away’

Three participants described examples of how they felt that their problems had been dealt with very promptly (P1, P2, P3). Interestingly, there was some overlap with theme E1, as participants cited examples in which the close relationship that they had with their named BMT nurse facilitated efficient care: ‘I think that it's probably the availability of [named BMT nurse] on the end of the phone that, you know,…you can have a friendly voice that knows you, so I think a personal relationship is important. And the fact that she has access to all of the other colleagues that she can then go and speak to and get back to me’ (P3). In contrast to most accounts of ‘attentive care’ (P3) and things being dealt with ‘very quickly’ (P1), one participant (P6) felt that on one occasion he contacted emergency triage services and felt that their failure to act on his concerns led to a delay in his GVHD diagnosis. The convenience of having a dermatologist embedded within the team, enabling streamlining of their GVHD care, was also referenced to by multiple participants (P2, 3, 5).

However, there were also descriptions of clinic delays and long waiting times at the hospital—particularly for blood tests (P1) and pharmacy (P1, P2, P7). Interestingly, these were largely discussed with a tone of sympathy for busy staff, or understanding of other urgent clinical need, rather than frustration: ‘Occasionally, it doesn’t happen very often now, but there are occasions where it is a long wait… But then I know that when I was poorly I had the attention of my consultant… there was no rush if you know what I mean, so I appreciate that there would be someone somewhere in with somebody who's very poorly and is taking a long time more, which I understand’ (P1). One participant (P2) described ‘niggly things’ with technology causing issues in clinic, and technical difficulties with prescribing the correct form of his medication (liquid rather than tablet). See Appendix 2, Table 9 for illustrative quotations.

Theme E3: Information provision—‘went into it with a bit of a rosy view’

This was a heterogeneous theme, with some participants feeling that they were given sufficient information (P3, P6, P7) while others would have appreciated more (P1, P2, P4, P5, P8). One participant who had their transplant many years ago felt that the information available now, with ever-increasing online resources, is far more detailed than was previously available (P4). Largely, participants felt that they were not prepared for the GVHD, but with the caveat that ‘I’m not sure anything quite prepares you for it’ (P8). Several participants felt that prior to the transplant, GVHD was ‘mentioned but not stressed’ (P3), with a greater focus on the actual transplant. Another participant (P6) explained that he thought this initial focus on the actual transplant, with further information about GVHD subsequently, was the right approach. In contrast to the prevailing view, one individual (P5) felt that what he imagined of GVHD was worse than he experienced and therefore would have appreciated more information beforehand as a means of reassurance.

In terms of ongoing provision of information during treatment of GVHD, there was an overlap with the idea of ‘attentive care’ addressed in theme E2. One participant (P5) explained how he is given plenty of reminders about how to manage his condition, for example with repeated reminders of the importance of adequate sun protection. However, another participant (P8) described a concerning time in which he experienced proximal myopathy from corticosteroid treatment, but he had not been informed this was a treatment side-effect, so he found the weakness he experienced very discouraging. He suggested that doctors should offer more information about possible treatment side-effects to prevent unnecessary worry in the event of side-effects occurring. Another participant suggested that having good information about the disease would help patients process the ‘ups and downs’ better and be ‘more proactive about their care’ (P5). See Appendix 2, Table 10 for illustrative quotations.

Theme E4: The role of support groups

Many participants discussed how speaking to other people who also had experiences of GVHD had been beneficial (P2, P3, P4, P5), or thought that they would benefit from it (P1). There was a sense of the value of shared experience that cannot be replaced by medical expertise alone. One participant (P3) described attending a support group as a ‘sobering’ and ‘scary’ experience and that his wife in fact ‘found it off-putting and alarming’, due to the fact that members of the group described symptoms far worse than he had experienced. The same participant did also say, however, that the meeting gave him more confidence regarding the possible treatment options for GVHD. Another patient (P6) did not feel that support groups would be valuable to him, although he was ‘open to it’, because he already had good support from his family. Illustrative quotations are presented in Appendix 2, Table 11.


Five themes related to the specific QOL issues experienced by individuals with GVHD were identified from our thematic analysis with four themes relating to patient experience of the specialist multidisciplinary BMT service.

A striking feature of the data is the variation in symptoms described and the extent to which these symptoms affect the patients’ day-to-day lives, which reflects the known heterogeneous nature of the condition [24]. Indeed, the concept of the distinct lack of uniformity and unpredictability of the condition was what most united the individual participants’ stories. The ambiguity of cGVHD has also been identified as a key theme in previous qualitative work exploring the psychosocial and emotional impact of cGVHD experienced by patients [11], and in survivors of HSCT more generally [12]. The sub-theme ‘adapting to sick role’ emerged from several of the participants’ accounts. We suggest that the unpredictability of the disease course of GVHD makes this adaptation particularly challenging, with constant adjustment of treatment dosing regimens and unpredictability of flare-ups meaning patients have to adapt to a continuously evolving sick role. Indeed, Moss-Morris [25] postulates that ‘self-efficacy/sense of control regarding disease management’ is an important factor in successful adaptation to a long-term condition.

Participants describe highly positive experiences of the care that they receive from a multidisciplinary BMT service, with efficiency, attentive and personal care being cited throughout. The convenience of having a dermatologist embedded within the team, enabling streamlining of patients’ GVHD care, is particularly pertinent when interpreted in parallel to the QOL data, in which some participants cited frequent and time-consuming hospital attendances as a factor restricting their normal lives. The positive healthcare experiences cited in these interviews is in contrast to a U.S focus group in 2005 where ‘betrayal by their medical team (inability to help them)’ was identified as a key theme in cGVHD patients [17], and in focus groups exploring healthcare needs of survivors of HSCT more broadly, participants felt ‘left on their own’ without targeted care for their specialist needs [18]. These reports emphasise the issues patients can face with their healthcare service when living with a ‘difficult-to-treat’ chronic disease and the pertinence of multidisciplinary specialist care. As this is the first qualitative study exploring patient experience of multidisciplinary specialist healthcare provision for GVHD in the U.K., it is difficult to interpret whether this contrast could result from international differences in practices, or simply a difference in the U.K. service we investigated versus those particular services in the U.S.

Dunn proposed as a result of her in-depth phenomenological work exploring the experiences of individuals returning home following allogeneic stem cell transplantation [9] that the development of an Advanced Nurse Practitioner skilled in early recognition of treatment effects would be highly beneficial in the care of patients in their first year post HSCT. In support of this, we identified ‘Personal care and close relationship with BMT nurses’ as a key theme relating to patient experience of healthcare service provision and emphasise the value with which many of the patients placed on the importance of having someone who knew their story readily available to speak to.

Our study’s qualitative methodology enabled the complexity and the unique nature of an individual’s experience with GVHD to be revealed. For example, in descriptions such as frustrations regarding clinic delays or long waits for blood tests or pharmacy, the interview data captures important nuances such as the participants’ understanding of time pressures experienced by their healthcare service. Furthermore, the optimism held by many individuals, even in the face of concerns and anxiety about disease progression, was apparent. Indeed, in a qualitative descriptive study seeking how participants cope with living with moderate and severe chronic GVHD, Driscoll et al. identified ‘Positive Attitude, Gratitude and Mindfulness’ as a key theme [8]. Dunn also found that many patients cited feeling lucky to have received a stem cell transplant and expressed gratitude for being given ‘a second chance’ [9].

In a previous qualitative analysis of interviews with HSCT survivors with moderate to severe chronic GVHD conducted by Fishman et al. [10], patients explained that by seeking information and a greater understanding of their disease, it helped them to gain control over it. This was echoed in our analysis, with participants reflecting on the importance of being well-informed regarding possible treatment side-effects, and that comprehensive information helps patients to process what is frequently a tumultuous disease course. In a qualitative analysis specifically focussed on patient education, Jim et al. reported that late complications post HSCT were often unexpected, and patients felt unprepared for the extent to which GVHD could affect their lives [14], which was also captured in our theme ‘Information provision—went into it with a bit of a rosy view’. Our theme ‘the role of support groups’ has also been previously described, with patients expressing a desire to connect with other HSCT survivors [10, 12, 14].

Potential limitations

Participants were all recruited from the specialist GVHD clinic, as this was our group of interest, using a convenience sampling method. There is a potential response bias as patients who felt more positive about their overall experience may be more likely to participate in the study. In addition, the demographics of the patients recruited to the study may not be representative of the entire GVHD population. Our participants were recruited from a single tertiary BMT centre and were generally well-educated and mostly belonged to a high socio-economic class. Ashing-Giwa [26] developed a conceptual model of HRQOL, finding that socioeconomic status is an important determinant of QOL. It is therefore likely that QOL issues in patient groups from less affluent socioeconomic backgrounds will vary and will need further exploration. Recruitment for this study was challenging, as many patients did not want to participate due to the high morbidity of their disease and high burden of living with GVHD.

Another potential limitation of this study is that the interviews were conducted by a doctor, so participants might have felt obligated to give socially desirable responses when asked to critique aspects of their healthcare. This was mitigated for by the fact that the interviewer was an academic trainee not involved in the set-up or running of the clinic, and with whom the patients were not familiar. Participants were also assured at the beginning of the interview that their comments would be anonymised, and that any issues raised during the interview would not be discussed with their care team without their explicit consent.

Only eight participants were interviewed for this study. However, sample size in qualitative research is driven at achieving data saturation—the collection of qualitative data to the point where a sense of closure is attained because new data yield redundant information [27]. Whilst we did not reach complete saturation of new ideas, we increasingly found overlap between issues and nine key themes arose. Indeed, the intention of this study was not to compile an exhaustive list of possible GVHD-related issues, nor describe the experience of every GVHD patient. Instead, our aim was to explore individual experiences of living with and being treated for GVHD, as an initial qualitative exploration of this complex systemic disease. Moser and Korstjens [27] suggest in their frequently cited ‘practical guidance to qualitative research’ that phenomenological studies ‘require fewer than 10 interviews’.


GVHD is a challenging disease to manage due to the highly heterogenous nature of its presentation, and the varied experience of the disease in patients. Significant QOL issues in this group include feelings of uncertainty about the nature of GVHD and its progression, the struggle to accept new restrictions to daily life and adaptation to the ‘sick role’ and coping with troubling symptoms. The importance of robust information provision was prominent throughout, with one participant suggesting that it enables a patient to better process the tumultuous course of the disease, and echoing findings in previous qualitative literature that a greater understanding of the disease can help with gaining back a sense of control. This does, of course, have to be carefully balanced with the risk of overburdening individuals with predictions in what is ultimately a highly unpredictable disease, and we emphasise the importance of a nuanced, flexible and personalised approach.

Participants in this study highly valued the multidisciplinary care team, including having a dermatologist embedded within the service, enabling streamlining of their GVHD care. The important role played by BMT specialist nurses who acted as gate-keepers for their care was particularly dominant throughout the interviews. Whilst further qualitative research is needed to develop our understanding of the complex issues, we suggest that BMT specialist nurses have an important role to play in managing the unique QOL issues of GVHD patients. BMT specialist nurses are also likely to promote the provision of high-quality information, and participants stated a preference for speaking to healthcare professionals who were familiar with their story and thus able to offer more personalised advice. With many services increasingly embracing the use of remote consultations and telemedicine, we emphasise the importance of maintaining these invaluable relationships remotely.

Availability of data and materials

All data generated or analysed during this study are included in this published article and its supplementary information files.



Graft-versus-host disease


Acute graft-versus-host disease


Chronic graft-versus-host disease


Haematopoietic stem cell transplantation


Patient-reported outcome measures


Quality of life


  1. Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 diagnosis and staging working group report. Biol Blood Marrow Transplant. 2015;21(3):389-401.e1.

    Article  PubMed  Google Scholar 

  2. The Biology of Chronic Graft-versus-Host Disease: a task force report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease—ScienceDirect [Internet].

  3. Lee SJ, Kim HT, Ho VT, Cutler C, Alyea EP, Soiffer RJ, et al. Quality of life associated with acute and chronic graft-versus-host disease. Bone Marrow Transplant. 2006;38(4):305–10.

    Article  CAS  PubMed  Google Scholar 

  4. Fatobene G, Storer BE, Salit RB, Lee SJ, Martin PJ, Cheng G-S, et al. Disability related to chronic graft-versus-host disease after alternative donor hematopoietic cell transplantation. Haematologica. 2019;104(4):835–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Pidala J, Kurland B, Chai X, Majhail N, Weisdorf DJ, Pavletic S, et al. Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. Blood. 2011;117(17):4651–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Lee SJ, Onstad L, Chow EJ, Shaw BE, Jim HSL, Syrjala KL, et al. Patient-reported outcomes and health status associated with chronic graft-versus-host disease. Haematologica. 2018;103(9):1535–41.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Kilgour J, Wali G, Gibbons E, Scherwath A, Barata Badiella A, Peniket A, et al. Systematic review of patient-reported outcome measures in graft-versus-host disease. Biol Blood Marrow Transplant. 2020;26(5):e113–27.

    PubMed  Google Scholar 

  8. Driscoll JP, Barron A-M, McGee E, Fishman S, El-Jawahri AR. Coping with moderate and severe chronic graft versus host disease. Biol Blood Marrow Transplant. 2017;23(3):S160.

    Article  Google Scholar 

  9. Dunn L. Safe in the bubble, out into the unknown : returning home following allogeneic stem cell transplantation. A phenomenological study [doctoral]. University of Surrey; 2015.

  10. Fishman S, El-Jawahri A, Traeger L, VanDusen H, Chen Y-BA, Temel JS, et al. Coping with moderate to severe chronic graft-versus-host disease (cGVHD) among hematopoietic stem cell transplant (HCT) survivors: a qualitative analysis. J Clin Oncol. 2016;34(26):257–257.

    Google Scholar 

  11. Galbizo E, Williams L, Whisenant M. The psychosocial and emotional impact of chronic graft-versus-host-disease. Oncol Nurs Forum. 2007;34(1):249.

    Google Scholar 

  12. Sherman RS, Cooke E, Grant M. Dialogue among survivors of hematopoietic cell transplantation. J Psychosoc Oncol. 2005;23(1):1–24.

    PubMed  Google Scholar 

  13. Hwang JP, Roundtree AK, Giralt SA, Suarez-Almazor M. Late effects and healthcare needs of survivors of allogeneic stem cell transplantation: a qualitative study. BMJ Support Palliat Care. 2012;2(4):344–50.

    PubMed  PubMed Central  Google Scholar 

  14. Jim HSL, Quinn GP, Gwede CK, Cases MG, Barata A, Cessna J, et al. Patient education in allogeneic hematopoietic cell transplant: what patients wish they had known about quality of life. Bone Marrow Transplant. 2014;49(2):299–303.

    CAS  PubMed  Google Scholar 

  15. Poloméni A, Lapusan S, Bompoint C, Rubio MT, Mohty M. The impact of allogeneic-hematopoietic stem cell transplantation on patients’ and close relatives’ quality of life and relationships. Eur J Oncol Nurs. 2016;1(21):248–56.

    Google Scholar 

  16. Russell C, Harcourt D, Henderson L, Marks DI. Patients’ experiences of appearance changes following allogeneic bone marrow transplantation. Cancer Nurs. 2011;34(4):315–21.

    PubMed  Google Scholar 

  17. Simoneau T, Rubinson T, Myers P, Alpert J. A focus group to identify problems associated with chronic graft versus host disease (cGVHD): P19–16. Psychooncology [Internet]. 2005 Jan [cited 2020 Jun 2];14.

  18. Suarez-Almazor M, Roundtree AK, Giralt S. A qualitative study of late effects and healthcare needs of survivors of stem cell transplantation. Abstr 2011 Int MASCCISOO Symp Support Care Cancer; 2011.

  19. Dignan FL, Amrolia P, Clark A, Cornish J, Jackson G, Mahendra P, et al. Diagnosis and management of chronic graft-versus-host disease. Br J Haematol. 2012;158(1):46–61.

    Article  CAS  PubMed  Google Scholar 

  20. Matin RN, Danby R, Gibbons E, Venning V, Rowley L, Barton D, et al. Developing a dedicated dermatology service for allogeneic bone marrow transplant recipients. Br J Dermatol. 2017;177(6):1758–9.

    CAS  PubMed  Google Scholar 

  21. Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77–101.

    Google Scholar 

  22. Making sense of qualitative data analysis: an introduction with illustrations from DIPEx (personal experiences of health and illness) | Request PDF [Internet]. ResearchGate.

  23. O’Brien BC, Harris IB, Beckman TJ, Reed DA, Cook DA. Standards for reporting qualitative research: a synthesis of recommendations. Acad Med. 2014;89(9):1245.

    PubMed  Google Scholar 

  24. Cooke KR, Luznik L, Sarantopoulos S, Hakim FT, Jagasia M, Fowler DH, et al. The biology of chronic graft-versus-host disease: a task force report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2017;23(2):211–34.

    Google Scholar 

  25. Moss-Morris R. Adjusting to chronic illness: time for a unified theory. Br J Health Psychol. 2013;18(4):681–6.

    PubMed  Google Scholar 

  26. Ashing-Giwa KT. The contextual model of HRQoL: a paradigm for expanding the HRQoL framework. Qual Life Res. 2005;14(2):297–307.

    PubMed  Google Scholar 

  27. Moser A, Korstjens I. Series: practical guidance to qualitative research. Part 3: sampling, data collection and analysis. Eur J Gen Pract. 2017;24(1):9–18.

    PubMed  PubMed Central  Google Scholar 

Download references


The authors would like to acknowledge Professor Ray Fitzpatrick, Professor of Public Health and Primary Care, University of Oxford, for his pre-submission review of the manuscript.


Funding for this research was received from the Oxfordshire Health Services Research Committee (Grant Reference 1304).

Author information

Authors and Affiliations



JK and RM conceived the study design. JK wrote the protocol and supporting documentation including interview schedule, with input from RM. RM and JK recruited participants and JK conducted the interviews. IDVH completed the analysis of the interview transcripts and developed the coding framework with input from JK. IDVH and JK wrote the manuscript with critical revision by RM, RD & AP. All authors read and approved the final manuscript.

Corresponding author

Correspondence to James M. Kilgour.

Ethics declarations

Ethics approval and consent to participate

Ethical approval for human subject research was granted by the North West—Preston NHS Research Ethics committee in April 2019 (reference 19/NW/0198).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


Appendix 1: Interview schedule


“Thank you for agreeing to this interview, which is being conducted to investigate the quality of life of patients with Graft-versus-Host Disease, also known as GVHD, following stem cell transplant. This interview will last for up to 1 h and will be in two sections. In the first section, we will explore how your quality of life has been affected by a diagnosis of GVHD. In the second section, we will explore how you have found the clinical services that are available for patients with GVHD, including the bone marrow transplant clinics here in Oxford and any support services that you have used.”

  1. 1.

    To begin with, could you please tell me a little bit about yourself, why and when you had the stem cell transplant and when you were diagnosed with GVHD?

Section A: Health-related quality of life issues of GVHD

“So now that we have discussed a bit of the background, we will move on to the first section of the interview, which focuses on quality of life”.

  1. 1.

    What does the term ‘quality of life’ mean to you?

  2. 2.

    Do you think the GVHD has affected your quality of life, and if so, how?

  3. 3.

    Has the way in which GVHD has affected your quality of life changed over time since you were diagnosed?

  4. 4.

    What symptoms have you experienced from the GVHD, and how have these affected you?

  5. 5.

    Have your symptoms changed over time? Have they changed in severity?

  6. 6.

    Other than physical symptoms, has the GVHD had an emotional impact on you?

  7. 7.

    As a result of the GVHD, have you had to make any lifestyle changes?

  8. 8.

    Are there any activities or hobbies that you used to enjoy that you can no longer do or have had to change as a result of the GVHD?

  9. 9.

    Has the GVHD had any impact on your partner (if applicable), family members and other relationships?

  10. 10.

    Has the GVHD affected your work or professional life (if applicable)?

  11. 11.

    Has the GVHD led to any financial problems?

  12. 12.

    How have you found the treatments for your GVHD? Have the treatments affected your quality of life? Have you had any side effects from them?

  13. 13.

    How do you see your future?

  14. 14.

    Is there anything else you would like to tell me before we move on to the next section of the interview?

Section B: Patient experience of current clinical services and supportive care provision

“Thank you for answering my questions so far, I’d like to now move on to the second section of the interview, which is focused on your experience of the clinical services available for GVHD patients”.

  1. 1.

    Could you please tell me about your experience with the care that you have received for your GVHD?

  2. 2.

    How did you find the bone marrow transplant clinic here in Oxford?

  3. 3.

    Has anything about your care been particularly good?

  4. 4.

    Is there anything that you think could be better about the care you have received to manage your GVHD?

  5. 5.

    Other than the bone marrow transplant clinic, have you had treatment or support for your GVHD from anyone else? This could include your GP, other hospital doctors, physiotherapists, psychologists or complementary medicine practitioners.

  6. 6.

    Are there other support services that you think should be available to GVHD patients?

  7. 7.

    Is there anything else you would like to talk about in terms of care that is currently provided for GVHD patients in this region?


“Thank you very much for your time today in answering my questions about GVHD. Our hope is that this research will make an important contribution to improving the future care of patients with Graft-versus-Host-Disease. If any of the topics that we have discussed today have been difficult or upsetting, then please let me know and we can discuss these issues, and I can offer you options for further support. Do you have any questions?”.

Appendix 2: Tables of Illustrative Quotations

See Tables 3, 4, 5, 6, 7, 8, 9, 10 and 11.

Table 3 Illustrative data extracts from theme Q1: ‘Restricted as to what I can do’
Table 4 Illustrative data extracts from theme Q2: Troubling symptoms—you can sort of get GVHD anywhere’
Table 5 Illustrative data extracts from theme Q3: Confusion and uncertainty regarding GVHD symptoms—‘Is this the GVHD?’
Table 6 Illustrative data extracts from theme Q4: Unpredictable course and uncertainty regarding the future
Table 7 Illustrative data extracts from sub-theme Q5: Adapting to the sick role
Table 8 Illustrative data extracts from theme E1: Personal care and close relationship with BMT nurses
Table 9 Illustrative data extracts from theme E2: Efficiency versus long waiting times—‘On the case straight away’
Table 10 Illustrative data extracts from theme E3: Information provision—‘went into it with a bit of a rosy view’
Table 11 Illustrative data extracts from theme E4: The role of support groups

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

de Vere Hunt, I., Kilgour, J.M., Danby, R. et al. “Is this the GVHD?” A qualitative exploration of quality of life issues in individuals with graft-versus-host disease following allogeneic stem cell transplant and their experiences of a specialist multidisciplinary bone marrow transplant service. Health Qual Life Outcomes 19, 11 (2021).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: